Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors

Sonidegib is a selective inhibitor of Smoothened receptor, which is a key regulator of the Hedgehog signaling pathway. The purpose of this study was to determine the maximum tolerated dose based on dose‐limiting toxicity (DLT) and the recommended dose (RD) of sonidegib in Asian patients with advance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Minami, Hironobu, Ando, Yuichi, Ma, Brigette Buig Yue, Hsiang Lee, Jih‐, Momota, Hiroyuki, Fujiwara, Yutaka, Li, Leung, Fukino, Koichi, Ito, Koji, Tajima, Takeshi, Mori, Asuka, Lin, Chia‐Chi
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5084670/
https://ncbi.nlm.nih.gov/pubmed/27467121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13022
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados